Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1093/ckj/sfw100 http://scihub22266oqcxt.onion/10.1093/ckj/sfw100 C5469552!5469552!28638601     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Clin+Kidney+J 2017 ; 10 (1): 16-9 Nephropedia Template TP {{tp|p=28638601|t=2017. The efficacy of rituximab in adult frequently relapsing minimal change disease |pdf=|usr=}}{{28638601}} gab.com Text The efficacy of rituximab in adult frequently relapsing minimal change disease JO: Clin Kidney J http://www.kidney.de/pget.php?&tw=1&pmid=28638601 #FOAvip Background: Corticosteroids are the basis of treatment for nephrotic syndrome due to minimal change disease (MCD), but 25% of patients have frequently relapsing nephrotic syndrome (FRNS) and 30% become steroid dependent. Prolonged use of conventional immunosuppressants causes significant toxicity. Rituximab (RTX) is now included in guidelines for childhood MCD. Evidence for use in adult MCD is limited. We describe a single-centre experience of RTX use in adult MCD. Methods: Outcomes of all adult MCD patients treated with RTX for FRNS between 2008 and 2015 were retrospectively analysed. Results: Thirteen patients received RTX; 11/13 had childhood-onset MCD. All had FRNS and 10 were steroid dependent. Eleven patients experienced one or more major treatment side effect from conventional therapy. At the time of RTX treatment, six patients were relapsing. All entered remission after RTX. The median length of follow-up after the first RTX treatment was 20 months (range 6?85). After RTX, the rate of relapse was reduced from 4 to 0.4/year (Wilcoxon signed rank P ? 0.05). Seven patients relapsed after RTX after a median of 10 months (range 1?11). All seven relapsing patients were successfully re-treated with RTX and none developed RTX-resistant nephrosis. The median number of courses of RTX per patient was 1 (range 1?5). The number of additional immunosuppressants, steroid dependency and antihypertensive agents were also reduced. At the last follow-up, two patients remained on low-dose steroids. No RTX-related adverse events were observed. Conclusion: RTX is safe and effective in adults with FRNS due to MCD. The median rate of relapse is significantly reduced following RTX treatment and additional immunosuppressant exposure is minimized. Twit Text FOAVip The efficacy of rituximab in adult frequently relapsing minimal change disease ????Clin Kidney J http://www.kidney.de/pget.php?&tw=1&pmid=28638601 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=28638601 #FOAvip English Wikipedia <ref>{{Cite pmid|28638601}}</ref> The efficacy of rituximab in adult frequently relapsing minimal change disease #MMPMID28638601 King C; Logan S; Smith SW; Hewins P Clin Kidney J 2017[Feb]; 10 (1): 16-9 PMID28638601show ga Background: Corticosteroids are the basis of treatment for nephrotic syndrome due to minimal change disease (MCD), but 25% of patients have frequently relapsing nephrotic syndrome (FRNS) and 30% become steroid dependent. Prolonged use of conventional immunosuppressants causes significant toxicity. Rituximab (RTX) is now included in guidelines for childhood MCD. Evidence for use in adult MCD is limited. We describe a single-centre experience of RTX use in adult MCD. Methods: Outcomes of all adult MCD patients treated with RTX for FRNS between 2008 and 2015 were retrospectively analysed. Results: Thirteen patients received RTX; 11/13 had childhood-onset MCD. All had FRNS and 10 were steroid dependent. Eleven patients experienced one or more major treatment side effect from conventional therapy. At the time of RTX treatment, six patients were relapsing. All entered remission after RTX. The median length of follow-up after the first RTX treatment was 20 months (range 6?85). After RTX, the rate of relapse was reduced from 4 to 0.4/year (Wilcoxon signed rank P ? 0.05). Seven patients relapsed after RTX after a median of 10 months (range 1?11). All seven relapsing patients were successfully re-treated with RTX and none developed RTX-resistant nephrosis. The median number of courses of RTX per patient was 1 (range 1?5). The number of additional immunosuppressants, steroid dependency and antihypertensive agents were also reduced. At the last follow-up, two patients remained on low-dose steroids. No RTX-related adverse events were observed. Conclusion: RTX is safe and effective in adults with FRNS due to MCD. The median rate of relapse is significantly reduced following RTX treatment and additional immunosuppressant exposure is minimized. äThe efficacy of rituximab in adult frequently relapsing minimal change(epmc).pdf DeepDyve Pubget Overpricing